Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electrochemotherapy vs cetuximab + platinum + 5-fluorouracil in recurrent oral/oropharyngeal squamous cell carcinoma
2018-003589-15Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Nov 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bleomycin, cetuximab, cisplatin, carboplatin and fluorouracil in Oral Mucosal Carcinoma and oropharyngeal squamous cell carcinoma (OPSCC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Objective response rate. Started Nov 2018; status: active.
02
Drugs
bleomycincetuximabcisplatincarboplatinfluorouracil
03
Conditions
Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2018-003589-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003589-15.